Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease
Table 5
Histological disease activity at baseline and follow-up in patients with and without fibrosis progression. Fibrosis stage was determined in all biopsies.
Parameter
No fibrosis progression (mean)
SD
Fibrosis progression (mean)
SD
value
Baseline
Steatosis (1–3)
1.73
0.94
1.79
0.88
0.88
Lobular inflammation (0–3)
1.43
0.85
1.33
0.7
0.63
Ballooning (0–2)
0.97
0.85
0.88
0.85
0.69
NAS (0–8)
3.86
2.31
3.84
2.17
0.92
Fibrosis (0–4)
1.47
1.16
1.15
1.04
0.28
NASH (number of patients, %)
19/30
63%
14/24
58%
0.78
Follow-up∗
Steatosis (1–3)
1.21
0.93
1.12
0.78
0.83
Lobular inflammation (0–3)
1.17
0.92
1.29
0.69
0.52
Ballooning (0–2)
0.54
0.78
0.94
0.83
0.11
NAS (0–8)
2.92
1.98
3.35
1.73
0.43
Fibrosis (0–4)
1.18
1.11
2.81
1.17
<0.001
NASH (number of patients, %)
10/24
42%
9/17
53%
0.54
∗54 biopsies were available for scoring of NASH at baseline and 41 at follow-up. Abbreviations: NAS: NAFLD activity score; NASH: nonalcoholic steatohepatitis; SD: standard deviation.
